

Carolyn S P Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8092300/publications.pdf>

Version: 2024-02-01

456
papers

43,896
citations

3159

92
h-index

2828

191
g-index

473
all docs

473
docs citations

473
times ranked

26071
citing authors

#	ARTICLE	IF	CITATIONS
1	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	1.8	11
2	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 50-59.	3.3	6
3	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022, 243, 11-14.	2.7	2
4	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	3.8	5
5	Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease. <i>Value in Health</i> , 2022, 25, 451-460.	0.3	4
6	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. <i>JACC: Heart Failure</i> , 2022, 10, 1-11.	4.1	11
7	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2022, 145, 565-574.	1.6	59
8	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	11.4	29
9	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2022, 4, e46-e54.	12.3	62
10	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
11	Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1255-1263.	1.7	12
12	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <sc>REPORTâ€HF</sc> registry. <i>European Journal of Heart Failure</i> , 2022, 24, 645-652.	7.1	18
13	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	7.1	30
14	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 681-684.	7.1	16
15	Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2022, 27, 1933-1955.	3.9	12
16	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	7.1	41
17	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	7.1	820
18	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reducedâ€Ejectionâ€Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	4.1	115

#	ARTICLE	IF	CITATIONS
19	Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort. <i>Advances in Therapy</i> , 2022, 39, 1432-1445.	2.9	3
20	Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 830-839.	0.9	3
21	How to Incorporate Sex and Gender Into the Design of Cardiovascular Clinical Trials. <i>Circulation</i> , 2022, 145, 499-501.	1.6	4
22	Heart Failure Subtypes and Cardiomyopathies in Women. <i>Circulation Research</i> , 2022, 130, 436-454.	4.5	28
23	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. <i>Circulation</i> , 2022, 145, 693-712.	1.6	57
24	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	4.1	75
25	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	7.1	16
26	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure. <i>Frontiers in Immunology</i> , 2022, 13, 817514.	4.8	7
27	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	3.1	4
28	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.	4.1	18
29	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2224-2234.	2.2	22
30	Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial. <i>European Journal of Heart Failure</i> , 2022, , .	7.1	8
31	Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002-2019). <i>The Lancet Regional Health - Western Pacific</i> , 2022, 22, 100417.	2.9	7
32	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. <i>Heart</i> , 2022, 108, 1200-1208.	2.9	10
33	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	1.2	40
34	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from the REPORT-HF (International Registry to assess Medical Practice with) <i>European Journal of Heart Failure</i> , 2022, , .	7.1	12
35	Association of Cardiovascular Health Metrics With Risk of Transition to Hypertension in Non-Hypertensive Young Adults. <i>American Journal of Hypertension</i> , 2022, 35, 858-866.	2.0	9
36	Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 857360.	2.4	3

#	ARTICLE	IF	CITATIONS
37	Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 1346-1356.	7.1	26
38	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	3.1	15
39	Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Long-Term Prognostic Implications for Death and Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e024060.	3.7	1
40	Association of Female Menopause With Atrioventricular Mechanics and Outcomes. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 804336.	2.4	2
41	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> , 2022, 9, 2753-2761.	3.1	7
42	Heart failure with normal LVEF in BIOSTAT-CHF. <i>International Journal of Cardiology</i> , 2022, 364, 85-90.	1.7	1
43	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	7.1	10
44	Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. <i>Scientific Reports</i> , 2022, 12, .	3.3	14
45	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	10
46	Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. <i>Diabetes and Metabolism</i> , 2022, 48, 101367.	2.9	15
47	Clinical implications of the universal definition for the prevention and treatment of heart failure. <i>Clinical Cardiology</i> , 2022, 45, .	1.8	1
48	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1614-1622.	7.1	15
49	Sex, fat and the heart: it's all in the waist. <i>European Journal of Heart Failure</i> , 2022, 24, 1371-1376.	7.1	1
50	Response by Lam and Gerstein to Letter Regarding Article, "Efgpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial". <i>Circulation</i> , 2022, 146, .	1.6	0
51	Re-examining the widespread policy of stopping sodium-glucose cotransporter ² inhibitors during acute illness: A perspective based on the updated evidence. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2071-2080.	4.4	16
52	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	3.8	108
53	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 648-656.	7.1	13
54	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 937-945.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Design and baseline characteristics of the <scp>AMPLITUDEâ€œ</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	4.4	12
56	Heart Disease in Women: Where Are We Now and What is The Future?. Heart Lung and Circulation, 2021, 30, 1-2.	0.4	1
57	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clinical Chemistry, 2021, 67, 216-226.	3.2	13
58	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
59	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	2.2	114
60	QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. Cardiology Journal, 2021, 28, 166-169.	1.2	1
61	Heart failure or heart success?. Cardiovascular Research, 2021, 117, e29-e34.	3.8	4
62	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	7.1	36
63	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	4.1	6
64	Contemporary economic burden in a realâ€world heart failure population with Commercial and Medicare supplemental plans. Clinical Cardiology, 2021, 44, 646-655.	1.8	17
65	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	3.3	5
66	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Scientific Reports, 2021, 11, 4885.	3.3	31
67	Association of sodiumâ€glucose cotransporterâ€2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1431-1435.	4.4	12
68	Epicardial fat in heart failure with reduced versus preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 835-838.	7.1	30
69	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIANâ€HF Registry. Journal of the American Heart Association, 2021, 10, e017932.	3.7	3
70	Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ, The, 2021, 372, n461.	6.0	83
71	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	7.1	630
72	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 983-991.	7.1	70

#	ARTICLE	IF	CITATIONS
73	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021, 42, 1464-1475.	2.2	29
74	Machine learning versus classic electrocardiographic criteria for the detection of echocardiographic left ventricular hypertrophy in a pre-participation cohort. <i>Kardiologia Polska</i> , 2021, 79, 654-661.	0.6	4
75	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006962.	2.2	13
76	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1570-1578.	2.9	11
77	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
78	Remote monitoring and digital health tools in CVD management. <i>Nature Reviews Cardiology</i> , 2021, 18, 457-458.	13.7	33
79	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	3.9	25
80	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 349-359.	4.1	14
81	BASILINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL. <i>Journal of the American College of Cardiology</i> , 2021, 77, 565.	2.8	1
82	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021, 397, 2385-2438.	13.7	530
83	Universal Definition and Classification of Heart Failure: Is It universal? Does It Define Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021, 27, 509-511.	1.7	9
84	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> (<sc>Vericiguat</sc> Global Study in Tj ETQq0 0 0 rg81/Overlook 10 Tf 50		
85	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <sc>DELIVER</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	7.1	195
86	Statin associated lower cancer risk and related mortality in patients with heart failure. <i>European Heart Journal</i> , 2021, 42, 3049-3059.	2.2	40
87	Classification of Heart Failure According to Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3217-3225.	2.8	56
88	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <sc>HEAAL</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1477-1484.	7.1	9
89	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	2.2	38
90	Associations of obesity and malnutrition with cardiac remodeling and cardiovascular outcomes in Asian adults: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003661.	8.4	29

#	ARTICLE	IF	CITATIONS
91	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	6.1	53
92	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2960-2972.	2.8	45
93	Subclinical vasculopathy and skeletal muscle metrics in the singapore longitudinal ageing study. <i>Aging</i> , 2021, 13, 14768-14784.	3.1	3
94	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021, 20, 159.	6.8	15
95	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021, 27, 1456-1461.	1.7	1
96	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021, 144, 159-169.	1.6	18
97	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	2.8	74
98	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	7.1	35
99	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2021, 18, 284-289.	3.3	10
100	Scientists on the Spot: A fraction of wisdom on heart failure. <i>Cardiovascular Research</i> , 2021, 117, e114-e115.	3.8	0
101	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021, 27, 756-765.	1.7	20
102	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	2.2	74
103	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. <i>European Heart Journal</i> , 2021, 42, 4420-4430.	2.2	65
104	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
105	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
106	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.2	5,558
107	Singapore's health-care system: key features, challenges, and shifts. <i>Lancet, The</i> , 2021, 398, 1091-1104.	13.7	64
108	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021, 8, 4572-4583.	3.1	21

#	ARTICLE	IF	CITATIONS
109	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	1.7	8
110	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	4.1	20
111	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in Heart Failure with Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	4.1	21
112	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	27.0	339
113	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662.	11.4	437
114	The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. <i>Global Heart</i> , 2021, 16, 22.	2.3	10
115	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. <i>Theranostics</i> , 2021, 11, 9243-9261.	10.0	13
116	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021414.	3.7	6
117	The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. <i>European Journal of Heart Failure</i> , 2021, 23, 1872-1874.	7.1	5
118	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108077.	2.3	3
119	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598.	2.8	23
120	Drug Layering in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 775-783.	4.1	32
121	Ventricular TLR4 Levels Abrogate TLR2-Mediated Adverse Cardiac Remodeling upon Pressure Overload in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11823.	4.1	6
122	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021094.	3.7	23
123	Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure. <i>JACC Asia</i> , 2021, 1, 303-313.	1.5	4
124	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	3.3	28
125	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	7.1	50
126	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 472-485.	7.1	71

#	ARTICLE	IF	CITATIONS
127	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	7.1	15
128	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 401.	6.1	51
129	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	7.1	26
130	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. <i>Circulation</i> , 2020, 141, 4-6.	1.6	81
131	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2020, 22, 751-754.	7.1	4
132	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 754-758.	7.1	4
133	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e012199.	3.7	55
134	A porcine model of heart failure with preserved ejection fraction: magnetic resonance imaging and metabolic energetics. <i>ESC Heart Failure</i> , 2020, 7, 93-103.	3.1	29
135	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
136	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. <i>JACC: Heart Failure</i> , 2020, 8, 212-222.	4.1	69
137	Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2020, 22, 646-660.	7.1	38
138	Reply in response to "Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions". <i>European Journal of Heart Failure</i> , 2020, 22, 385-386.	7.1	0
139	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	4.1	88
140	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.4	170
141	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117
142	A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. <i>Communications Biology</i> , 2020, 3, 697.	4.4	14
143	Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2240-2249.	3.1	17
144	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 1016-1021.	1.7	29

#	ARTICLE	IF	CITATIONS
145	Victims of Success in Failure. <i>Circulation</i> , 2020, 142, 1129-1131.	1.6	12
146	Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT-HF randomized clinical trial. <i>ESC Heart Failure</i> , 2020, 7, 3881-3890.	3.1	26
147	The Upcoming Epidemic of Heart Failure in South Asia. <i>Circulation: Heart Failure</i> , 2020, 13, e007218.	3.9	37
148	Cardiac and renal biomarkers in recreational runners following a 21-km treadmill run. <i>Clinical Cardiology</i> , 2020, 43, 1443-1449.	1.8	3
149	Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. <i>ESC Heart Failure</i> , 2020, 7, 2051-2062.	3.1	9
150	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1108-1109.	1.7	0
151	Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1770-1780.	1.6	43
152	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof-of-concept study. <i>ESC Heart Failure</i> , 2020, 7, 4267-4276.	3.1	3
153	Heart failure with preserved ejection fraction diagnostic scores in an Asian population. <i>European Journal of Heart Failure</i> , 2020, 22, 1737-1739.	7.1	14
154	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020, 7, 1419-1429.	3.1	6
155	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020, 318, 126-129.	1.7	18
156	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
157	P0816 CLINICAL CHARACTERISTICS AND EGFR AND UACR DISTRIBUTION ACCORDING TO THE 2012 KDIGO CKD CLASSIFICATION: A REPORT FROM THE US DISCOVER CKD COHORT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
158	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2020, 141, 1915-1926.	1.6	40
159	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 606-615.	11.4	67
160	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	4.1	14
161	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	2.8	46
162	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	2.2	47

#	ARTICLE	IF	CITATIONS
163	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1675-1683.	7.1	24
164	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	27.0	753
165	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	4.1	53
166	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	7.1	193
167	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. <i>European Journal of Heart Failure</i> , 2020, 22, 1586-1597.	7.1	16
168	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1956-1965.	3.1	43
169	Ethnic differences in quality of life and its association with survival in patients with heart failure. <i>Clinical Cardiology</i> , 2020, 43, 976-985.	1.8	8
170	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <i>BIOSTAT-CHF</i> and <i>ASIAN-CHF</i> registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	7.1	24
171	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075.	7.1	31
172	Risk Factors for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006472.	3.9	100
173	Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. <i>Circulation</i> , 2020, 141, 540-548.	1.6	195
174	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. <i>Circulation</i> , 2020, 141, 530-539.	1.6	62
175	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 834-844.	7.1	36
176	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020, 8, e411-e422.	6.3	104
177	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	4.1	25
178	Circulating neuregulin-1 in heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 445-455.	3.1	11
179	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014908.	3.7	161
180	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. <i>ESC Heart Failure</i> , 2020, 7, 996-1006.	3.1	10

#	ARTICLE	IF	CITATIONS
181	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	7.1	28
182	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020, 109, 1079-1098.	3.3	74
183	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2353-2355.	2.2	31
184	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 898-901.	7.1	59
185	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1551-1567.	7.1	93
186	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020, 15, 44.	2.3	11
187	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 261-266.	4.4	7
188	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019, 21, 23-36.	7.1	102
189	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019, 65, 1221-1227.	3.2	21
190	Heart failure around the world. <i>European Journal of Heart Failure</i> , 2019, 21, 1187-1196.	7.1	56
191	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013114.	3.7	69
192	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. <i>Lancet Public Health</i> , The, 2019, 4, e406-e420.	10.0	82
193	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.	8.6	52
194	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	4.1	77
195	Application of the H ₂ FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	7.1	18
196	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	2.8	97
197	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. <i>Cell</i> , 2019, 179, 736-749.e15.	28.9	126
198	Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2019, 25, S43.	1.7	0

#	ARTICLE	IF	CITATIONS
199	SGLT2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. <i>Journal of the American Heart Association</i> , 2019, 8, e013389.	3.7	119
200	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 140, 1359-1361.	1.6	16
201	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1912-1917.	1.6	13
202	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	13.7	159
203	Angiotensinâ€“Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	27.0	1,485
204	How to diagnose heart failure with preserved ejection fraction: the HFAâ€“PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	2.2	944
205	Choosing a Career in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006026.	3.9	2
206	Comparison of HeartLogic Heart Failure Diagnostic Sensor Measurements and Alerts between Patients with CRT-D and ICD Devices. <i>Journal of Cardiac Failure</i> , 2019, 25, S186.	1.7	0
207	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002916.	8.4	64
208	Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. <i>Heart</i> , 2019, 105, 842-847.	2.9	22
209	High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. <i>International Journal of Cardiology</i> , 2019, 282, 93-98.	1.7	8
210	A Populationâ€“wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian malesâ€“results from the Singapore Armed Forces ECG (SAFE) study. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12634.	1.1	17
211	Empagliflozin and Heart Failure. <i>Circulation</i> , 2019, 139, 2831-2834.	1.6	3
212	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019, 40, 3593-3602.	2.2	69
213	Cornell product is an ECG marker of heart failure with preserved ejection fraction. <i>Heart Asia</i> , 2019, 11, e011108.	1.1	9
214	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	3.9	33
215	Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , 2019, 12, e005855.	3.9	35
216	The diabetes-atrial fibrillation paradox. <i>Heart</i> , 2019, 105, 893.1-893.	2.9	3

#	ARTICLE	IF	CITATIONS
217	Particulate air pollution on cardiovascular mortality in the tropics: impact on the elderly. <i>Environmental Health</i> , 2019, 18, 34.	4.0	35
218	APPLICATION OF THE H2FPEF-SCORE TO A GLOBAL CLINICAL TRIAL OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 912.	2.8	1
219	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. <i>JAMA Cardiology</i> , 2019, 4, 515.	6.1	51
220	Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. <i>European Journal of Heart Failure</i> , 2019, 21, 685-688.	7.1	5
221	INITIATION OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS OTHER GLUCOSE LOWERING DRUGS AND RISK OF HOSPITALIZATION FOR HEART FAILURE AND DEATH IN PATIENTS WITH TYPE 2 DIABETES WITH REDUCED AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1705.	2.8	0
222	Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1300-1313.	2.8	68
223	Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. <i>Cardiovascular Research</i> , 2019, 115, 1791-1803.	3.8	25
224	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 306-317.	4.1	125
225	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 321-332.	4.1	33
226	Prediction of Survival in Asian Patients Hospitalized With Heart Failure: Validation of the OPTIMIZE-HF Risk Score. <i>Journal of Cardiac Failure</i> , 2019, 25, 571-575.	1.7	13
227	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1935-1940.	1.6	2
228	Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes. <i>European Journal of Heart Failure</i> , 2019, 21, 688-690.	7.1	16
229	Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology. <i>JACC: Heart Failure</i> , 2019, 7, 239-249.	4.1	82
230	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2539-2550.	2.8	69
231	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019, 4, 924-937.	4.1	24
232	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	2.8	138
233	Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). <i>BMC Cardiovascular Disorders</i> , 2019, 19, 259.	1.7	12
234	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 447-451.	1.4	9

#	ARTICLE	IF	CITATIONS
235	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	7.1	65
236	Sex differences in heart failure. <i>European Heart Journal</i> , 2019, 40, 3859-3868c.	2.2	406
237	Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized ¹³ C magnetic resonance spectroscopy study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 357-365.	4.4	52
238	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019, 40, 705-706.	2.2	1
239	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIANâ€HF registry. <i>European Journal of Heart Failure</i> , 2019, 21, 297-307.	7.1	36
240	Defining a â€frequent admitterâ€™ phenotype among patients with repeat heart failure admissions. <i>European Journal of Heart Failure</i> , 2019, 21, 311-318.	7.1	15
241	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 633-640.	2.3	33
242	An Eastâ€West comparison of self-care barriers in heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 615-622.	1.0	4
243	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019, 14, 197.	2.3	67
244	Use of Telemetry and Plethysmography to Assess Respiratory Function in Conscious Rats with Bleomycin-Induced Lung Fibrosis. , 2019, , .		0
245	Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 461-468.	3.9	4
246	Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. <i>International Journal of Cardiology</i> , 2018, 263, 88-93.	1.7	17
247	Prevalence, clinical correlates, and outcomes of anaemia in multiâ€ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 570-578.	3.1	21
248	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 254, 203-209.	1.7	14
249	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018, 39, 1770-1780.	2.2	194
250	Nâ€terminal proâ€Bâ€type natriuretic peptide and prognosis in <sc>Caucasian</sc> vs. <sc>Asian</sc> patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 279-287.	3.1	8
251	Heart failure with midâ€range ejection fraction: causes and consequences. <i>European Journal of Heart Failure</i> , 2018, 20, 660-662.	7.1	4
252	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	7.1	295

#	ARTICLE	IF	CITATIONS
253	Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). <i>ESC Heart Failure</i> , 2018, 5, 344-353.	3.1	37
254	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. <i>European Journal of Heart Failure</i> , 2018, 20, 738-747.	7.1	109
255	The women's heart health programme: a pilot trial of sex-specific cardiovascular management. <i>BMC Women's Health</i> , 2018, 18, 56.	2.0	9
256	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2628-2639.	2.8	370
257	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 425-432.	1.2	93
258	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239
259	Chronic obstructive pulmonary disease and ß-blocker treatment in Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 297-305.	3.1	11
260	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	7.1	41
261	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	4.1	141
262	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 621-627.	1.6	14
263	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018, 24, 177-185.	1.7	65
264	Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes. <i>European Journal of Heart Failure</i> , 2018, 20, 821-822.	7.1	2
265	Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking. <i>Circulation</i> , 2018, 137, 488-503.	1.6	30
266	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 812.	1.7	5
267	A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study. <i>Journal of Cardiac Failure</i> , 2018, 24, 811.	1.7	1
268	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
269	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.	1.6	52
270	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018, 20, 1664-1672.	7.1	92

#	ARTICLE	IF	CITATIONS
271	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e004540.	3.9	23
272	Causes of Death Among Patients with and without Diabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S69.	1.7	0
273	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018, 203, 25-29.	2.7	29
274	Multiethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1281-1289.	7.1	23
275	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 999-1007.	1.6	5
276	Iron deficiency in chronic heart failure: case-based practical guidance. <i>ESC Heart Failure</i> , 2018, 5, 764-771.	3.1	43
277	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
278	Fat, Female, Fatigued. <i>JACC: Heart Failure</i> , 2018, 6, 710-713.	4.1	14
279	Sex Differences in Cardiovascular Pathophysiology. <i>Circulation</i> , 2018, 138, 198-205.	1.6	302
280	Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2018, 19, 94.	4.1	23
281	Cardiac Structural Remodeling, Longitudinal Systolic Strain, and Torsional Mechanics in Lean and Nonlean Dysglycemic Chinese Adults. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007047.	2.6	26
282	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	6.3	113
283	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. <i>New England Journal of Medicine</i> , 2018, 379, 1332-1342.	27.0	265
284	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1035-1039.	2.3	3
285	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018, 39, 3439-3450.	2.2	375
286	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.2	47
287	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> . 2018. 20. 1303-1311.	7.1	138
288	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	2.2	250

#	ARTICLE	IF	CITATIONS
289	LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. <i>International Journal of Cardiology</i> , 2018, 271, 247-253.	1.7	19
290	Cardiovascular disease and multimorbidity: A call for interdisciplinary research and personalized cardiovascular care. <i>PLoS Medicine</i> , 2018, 15, e1002545.	8.4	23
291	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018, 15, e1002541.	8.4	97
292	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	2.2	83
293	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload. <i>JACC: Heart Failure</i> , 2017, 5, 157-165.	4.1	38
294	Differences in Presentation, Management and Outcomes in Women and Men Presenting to an Emergency Department With Possible Cardiac Chest Pain. <i>Heart Lung and Circulation</i> , 2017, 26, 1282-1290.	0.4	13
295	Asia-Pacific consensus statement on the optimal use of high-sensitivity troponin assays in acute coronary syndromes diagnosis: focus on hs-TnI. <i>Heart Asia</i> , 2017, 9, 81-87.	1.1	18
296	Heart Failure in Women: Risk Across a Woman's Adult Life. <i>Journal of Cardiac Failure</i> , 2017, 23, 379-381.	1.7	7
297	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	177
298	Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	12
299	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	7.1	84
300	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1664-1671.	7.1	224
301	Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2876-2878.	2.8	18
302	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	4.1	290
303	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	2.2	285
304	Fussing Over the Middle Child. <i>Circulation</i> , 2017, 135, 1279-1280.	1.6	38
305	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. CLINICAL PERSPECTIVE. <i>Circulation: Heart Failure</i> , 2017, 10, e003534.	3.9	14
306	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 14-24.	4.1	57

#	ARTICLE	IF	CITATIONS
307	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	4.1	129
308	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. <i>Journal of Controlled Release</i> , 2017, 247, 127-133.	9.9	104
309	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017, 19, 1651-1660.	7.1	89
310	Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	0
311	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. <i>European Journal of Heart Failure</i> , 2017, 19, 1483-1490.	7.1	42
312	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1624-1634.	7.1	196
313	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	7.1	67
314	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
315	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17058.	30.5	136
316	Membrane Proteomics of Impaired Energetics and Cytoskeletal Disorganization in Elderly Diet-Induced Diabetic Mice. <i>Journal of Proteome Research</i> , 2017, 16, 3504-3513.	3.7	6
317	The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1638-1647.	7.1	74
318	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. <i>European Journal of Heart Failure</i> , 2017, 19, 1732-1735.	7.1	6
319	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. <i>Scientific Reports</i> , 2017, 7, 9193.	3.3	23
320	Comparison of health state values derived from patients and individuals from the general population. <i>Quality of Life Research</i> , 2017, 26, 3353-3363.	3.1	10
321	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry [®] . <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
322	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRA [®] Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1637-1645.	1.8	109
323	Atrial Fibrillation in Heart Failure [®] . <i>JACC: Heart Failure</i> , 2017, 5, 575-577.	4.1	9
324	Medical Podcasting and <i>Circulation on the Run</i> . <i>Circulation</i> , 2017, 136, 513-515.	1.6	3

#	ARTICLE	IF	CITATIONS
325	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	38
326	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	4.1	238
327	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017, 191, 75-81.	2.7	31
328	Influenza-Associated Hospitalizations for Cardiovascular Diseases in the Tropics. <i>American Journal of Epidemiology</i> , 2017, 186, 202-209.	3.4	21
329	Obese Heart Failure With Preserved Ejection Fraction Phenotype. <i>Circulation</i> , 2017, 136, 20-23.	1.6	54
330	Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. <i>American Journal of Cardiology</i> , 2017, 120, 911-916.	1.6	32
331	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. <i>Journal of Cardiac Failure</i> , 2017, 23, 63-71.	1.7	17
332	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017, 19, 348-356.	7.1	38
333	Gender-differences in the associations between circulating creatine kinase, blood pressure, body mass and non-alcoholic fatty liver disease in asymptomatic asians. <i>PLoS ONE</i> , 2017, 12, e0179898.	2.5	17
334	Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 27-40.	2.6	36
335	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <i>European Journal of Heart Failure</i> , 2016, 18, 588-598.	7.1	242
336	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016, 102, 1464-1471.	2.9	15
337	Influence of Ethnicity, Age, and Time on Sex Disparities in Long-Term Cause-Specific Mortality After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	9
338	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
339	Heart failure with preserved ejection fraction in hypertension. <i>Current Opinion in Cardiology</i> , 2016, 31, 410-416.	1.8	33
340	Association of Age, Sex, Body Size and Ethnicity with Electrocardiographic Values in Community-based Older Asian Adults. <i>Heart Lung and Circulation</i> , 2016, 25, 705-711.	0.4	12
341	Paradoxical Low-Gradient Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2447-2448.	2.8	12
342	Racial Differences in Electrocardiographic Characteristics and Prognostic Significance in Whites Versus Asians. <i>Journal of the American Heart Association</i> , 2016, 5, e002956.	3.7	27

#	ARTICLE	IF	CITATIONS
343	High-Sensitivity Sandwich ELISA for Plasma NT-proUcn2: Plasma Concentrations and Relationship to Mortality in Heart Failure. <i>Clinical Chemistry</i> , 2016, 62, 856-865.	3.2	19
344	Impact of stock market volatility on mortality and cardiovascular events. <i>International Journal of Cardiology</i> , 2016, 223, 318-319.	1.7	6
345	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , 2016, 37, 3141-3153.	2.2	144
346	Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 81-88.	7.1	128
347	Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICEâ€ASIAâ€CHF). <i>ESC Heart Failure</i> , 2016, 3, 71-76.	3.1	10
348	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1472-1487.	7.1	200
349	Light to Moderate Habitual Alcohol Consumption Is Associated with Subclinical Ventricular and Left Atrial Mechanical Dysfunction in an Asymptomatic Population: Dose-Response and Propensity Analysis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 1043-1051.e4.	2.8	45
350	Random Plasma Glucose Levels and Cardiovascular Risk. <i>JAMA Cardiology</i> , 2016, 1, 823.	6.1	1
351	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2217-2228.	2.8	292
352	Impact of aortic root size on left ventricular afterload and stroke volume. <i>European Journal of Applied Physiology</i> , 2016, 116, 1355-1365.	2.5	11
353	Heart Failure Clinical Trials in East and Southeast Asia. <i>JACC: Heart Failure</i> , 2016, 4, 419-427.	4.1	48
354	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 502-510.	4.1	49
355	Understanding Heart Failure With Mid-Range Ejection Fraction â€“. <i>JACC: Heart Failure</i> , 2016, 4, 473-476.	4.1	36
356	Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. <i>Heart</i> , 2016, 102, 257-259.	2.9	59
357	Minding the Gap in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 50-54.	4.1	5
358	Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort. <i>PLoS ONE</i> , 2016, 11, e0148073.	2.5	31
359	Longitudinal Community-Based Study of QT Interval and Mortality in Southeast Asians. <i>PLoS ONE</i> , 2016, 11, e0154901.	2.5	7
360	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1-14.	1.7	13

#	ARTICLE	IF	CITATIONS
361	Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review. <i>Clinical Cardiology</i> , 2015, 38, 621-628.	1.8	76
362	Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. <i>European Heart Journal</i> , 2015, 36, 2050-2060.	2.2	126
363	Heart failure in Southeast Asia: facts and numbers. <i>ESC Heart Failure</i> , 2015, 2, 46-49.	3.1	89
364	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1577-1588.	3.1	46
365	Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 393-404.	7.1	160
366	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	7.1	50
367	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2015, 17, 135-143.	7.1	21
368	International Registry to assess medical Practice with Longitudinal observation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015, 17, 527-533.	7.1	52
369	Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 82, 13-21.	1.9	29
370	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	2.8	116
371	Impact of the joint association between sex, age and diabetes on long-term mortality after acute myocardial infarction. <i>BMC Public Health</i> , 2015, 15, 308.	2.9	9
372	Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 234-238.	2.0	53
373	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.8	148
374	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	7.4	288
375	Function over form? Assessing the left atrium in heart failure. <i>European Heart Journal</i> , 2015, 36, 711-714.	2.2	14
376	The Relationship among Carotid Artery Remodeling, Cardiac Geometry, and Serum N-Terminal Pro-B-Type Natriuretic Peptide Level in Asymptomatic Asians: Sex-Differences and Longitudinal GEE Study. <i>PLoS ONE</i> , 2015, 10, e0131440.	2.5	3
377	Electrocardiographic Criteria for Left Ventricular Hypertrophy in Asians Differs from Criteria Derived from Western Populations—Community-based Data from an Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 274-83.	0.4	5
378	Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001699.	8.4	198

#	ARTICLE	IF	CITATIONS
379	Rationale and design of the SOLuble guanylate Cyclase stimulator in heart failure Studies (SOCRATES). European Journal of Heart Failure, 2014, 16, 1026-1038.	7.1	119
380	Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. European Journal of Heart Failure, 2014, 16, 1125-1132.	7.1	104
381	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
382	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542.	7.1	184
383	The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). European Journal of Heart Failure, 2014, 16, 1049-1055.	7.1	172
384	The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	2.8	1,640
385	Developing Therapies for Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	4.1	267
386	Heart failure with preserved ejection fraction: a clinical dilemma. European Heart Journal, 2014, 35, 1022-1032.	2.2	178
387	Preface. Heart Failure Clinics, 2014, 10, xv.	2.1	8
388	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). Journal of Cardiac Failure, 2014, 20, S39.	1.7	0
389	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
390	What Is Normal in HFNEF?. JACC: Heart Failure, 2014, 2, 541-543.	4.1	5
391	ETHNICITY AND SEX-SPECIFIC ECHOCARDIOGRAPHIC AND ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY: COMMUNITY-BASED DATA FROM AN ASIAN POPULATION. Journal of the American College of Cardiology, 2014, 63, A1093.	2.8	0
392	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. American Heart Journal, 2014, 168, 142-149.	2.7	34
393	Physicians' Perception of the Patient Care Pathway for Acute Heart Failure in Asian Countries: Implications for Resource Allocation, Preventive Strategies and Clinical Trial Design. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, .	0.0	2
394	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, 8.	0.0	6
395	Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. Journal of Hypertension, 2014, 32, 174-180.	0.5	3
396	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1). Chest, 2014, 146, 1274-1285.	0.8	214

#	ARTICLE	IF	CITATIONS
397	Women and Heart Failure: An Emerging Venus-Mars Concept. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 212-216.	2.0	3
398	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2013, 19, 156-162.	1.7	61
399	Aortic Root Remodeling and Risk of Heart Failure in the Framingham Heart Study. <i>JACC: Heart Failure</i> , 2013, 1, 79-83.	4.1	54
400	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013, 34, 676-683.	2.2	59
401	How do patients with heart failure with preserved ejection fraction die?. <i>European Journal of Heart Failure</i> , 2013, 15, 604-613.	7.1	178
402	Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. <i>European Journal of Heart Failure</i> , 2013, 15, 928-936.	7.1	78
403	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	3.9	177
404	PREFERENCE FOR SYMPTOM VERSUS SURVIVAL IMPROVEMENT AMONG ASIAN PATIENTS WITH HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1917.	2.8	1
405	Endothelial Dysfunction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1787-1789.	2.8	77
406	Natriuretic peptides, gender and cardiovascular risk: What is the link?. <i>Maturitas</i> , 2012, 71, 89-91.	2.4	2
407	Variable phenotype in murine transverse aortic constriction. <i>Cardiovascular Pathology</i> , 2012, 21, 188-198.	1.6	69
408	Pulmonary Pressures and Death in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 222-231.	2.8	250
409	Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2012, 14, 1338-1347.	7.1	181
410	Sex and Cardiovascular Risk. <i>Circulation</i> , 2012, 126, 913-915.	1.6	9
411	Prognostic Utility of Metabolic Exercise Testing in Minimally Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2012, 109, 1494-1498.	1.6	63
412	Influence of Sex and Hormone Status on Circulating Natriuretic Peptides. <i>Journal of the American College of Cardiology</i> , 2011, 58, 618-626.	2.8	136
413	Bedside Assessment of Cardiac Hemodynamics: The Impact of Noninvasive Testing and Examiner Experience. <i>American Journal of Medicine</i> , 2011, 124, 1051-1057.	1.5	40
414	Ethnic Differences in Risk Prediction for Heart Failure Rehospitalization. <i>Journal of Cardiac Failure</i> , 2011, 17, S68.	1.7	0

#	ARTICLE	IF	CITATIONS
415	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011, 29, 1829-1836.	0.5	23
416	Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. <i>Heart</i> , 2011, 97, 964-969.	2.9	191
417	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. <i>Human Molecular Genetics</i> , 2011, 20, 1241-1251.	2.9	67
418	Cardiac Natriuretic Peptides, Obesity, and Insulin Resistance: Evidence from Two Community-Based Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3242-3249.	3.6	141
419	Epidemiology and clinical course of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2011, 13, 18-28.	7.1	569
420	Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community. <i>Circulation</i> , 2011, 124, 24-30.	1.6	274
421	The Socioeconomics of Hypertension. <i>Hypertension</i> , 2011, 58, 140-141.	2.7	18
422	Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 492-498.	5.1	19
423	Size, Shape, and Stamina. <i>Hypertension</i> , 2010, 55, 1143-1149.	2.7	35
424	Circulating Insulin-Like Growth Factor-1 and Its Binding Protein-3. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1479-1484.	2.4	81
425	Aortic Root Remodeling Over the Adult Life Course. <i>Circulation</i> , 2010, 122, 884-890.	1.6	155
426	Mineralocorticoid Accelerates Transition to Heart Failure With Preserved Ejection Fraction Via α -Nongenomic Effects. <i>Circulation</i> , 2010, 122, 370-378.	1.6	74
427	Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2010, 3, 588-595.	3.9	891
428	Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 845-854.	2.8	606
429	Left Ventricular Function and Exercise Capacity. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 286.	7.4	208
430	Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population. <i>Circulation</i> , 2009, 119, 2663-2670.	1.6	384
431	Coronary Sarcoidosis Presenting as Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2009, 32, E68-71.	1.8	26
432	Does a Normal BNP Exclude Heart Failure with Preserved Ejection Fraction?. <i>Journal of Cardiac Failure</i> , 2009, 15, S111.	1.7	1

#	ARTICLE	IF	CITATIONS
433	Reduced Metabolic Exercise Capacity Predicts Death and Heart Failure in Minimally Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2009, 15, S91-S92.	1.7	0
434	Chronic Indwelling Pleural Catheters Reduce Hospitalizations in Advanced Heart Failure with Refractory Pleural Effusions. <i>Journal of Cardiac Failure</i> , 2009, 15, S105.	1.7	13
435	Isolating the Renal Venous System from Systolic Reflux in Severe Tricuspid Regurgitation Using Transcatheter Valves. <i>Journal of Cardiac Failure</i> , 2009, 15, S50.	1.7	0
436	Pulmonary Artery Systolic Pressure Is an Independent Predictor of Exercise Capacity in Hypertrophic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2009, 15, S20.	1.7	0
437	Anti-Remodeling Effects of Chronic Phosphodiesterase-Type-5 Inhibition Are Dependent on Impaired cGMP-Dependent Protein Kinase Signaling. <i>Journal of Cardiac Failure</i> , 2009, 15, S3.	1.7	2
438	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1119-1126.	2.8	1,160
439	Contractility and Ventricular Systolic Stiffening in Hypertensive Heart Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 410-418.	2.8	372
440	The Mitral Annular Middiastolic Velocity Curve: Functional Correlates and Clinical Significance in Patients with Left Ventricular Hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 165-170.	2.8	11
441	Depressed Myocardial Contractility Despite Normal Chamber Systolic Function in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2008, 14, S14-S15.	1.7	0
442	Prevalence and Prognostic Significance of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Population-Based Study. <i>Journal of Cardiac Failure</i> , 2008, 14, S16-S17.	1.7	0
443	Ageing Versus Hypertension in Heart Failure with Preserved Ejection Fraction: Insights from Murine Models. <i>Journal of Cardiac Failure</i> , 2008, 14, S31-S32.	1.7	0
444	Impact of Aging on Pulmonary Hemodynamics in the General Population. <i>Journal of Cardiac Failure</i> , 2008, 14, S82-S83.	1.7	0
445	Response to Letter Regarding Article, "Cardiac Structure and Ventricular Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota." <i>Circulation</i> , 2007, 116, .	1.6	2
446	Revisiting methods for assessing and comparing left ventricular diastolic stiffness: impact of relaxation, external forces, hypertrophy, and comparators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2738-H2746.	3.2	18
447	Cardiac Structure and Ventricular Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota. <i>Circulation</i> , 2007, 115, 1982-1990.	1.6	475
448	Acute and Chronic Ventricular-Arterial Coupling in Systole and Diastole. <i>Hypertension</i> , 2007, 50, 503-511.	2.7	66
449	Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1193-1202.	2.8	122
450	Diastolic Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: A Population Based Study. <i>Journal of Cardiac Failure</i> , 2006, 12, S4.	1.7	1

#	ARTICLE	IF	CITATIONS
451	Invasive Characterization of Hemodynamic Events during Diastasis in Patients with Structural Heart Disease. <i>Journal of Cardiac Failure</i> , 2006, 12, S20-S21.	1.7	1
452	Cardiac Volumes in Patients with Heart Failure and Preserved Ejection Fraction: A Population Based Study. <i>Journal of Cardiac Failure</i> , 2006, 12, S23.	1.7	0
453	Matrix Metalloproteinases and Their Endogenous Inhibitors: Association with Ventricular Remodeling, Diastolic Dysfunction and Heart Failure in the Community. <i>Journal of Cardiac Failure</i> , 2006, 12, S32.	1.7	1
454	Comments on "the impact of SARS on medical house staff ...". <i>Journal of General Internal Medicine</i> , 2005, 20, 973-973.	2.6	1
455	The mitral L wave: A marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2005, 18, 336-341.	2.8	46
456	Teaching cardiac auscultation without patient contact. <i>Medical Education</i> , 2004, 38, 1184-1185.	2.1	7